Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: Haim R. Branisteanu who wrote (161422)	8/19/2020 4:04:21 PM
From: Pogeu Mahone	Respond to of 219497

FDA halts emergency approval of COVID-19 blood plasma treatment By Yaron Steinbuch August 19, 2020 \| 10:01am \| Updated Enlarge Image Melissa Cruz elevates her arm after donating blood plasma in April.Karen Ducey/Getty Images Sign up for our special edition newsletter to get a daily update on the coronavirus pandemic. MORE ON: CORONAVIRUS 'Survival does not mean that individuals fully recovered': Another warning from 1918 flu COVID go bragh: Ireland bar's 'appalling' brunch antics Batman prowls streets of Santiago delivering food to homeless De Blasio explains coronavirus uptick in Brooklyn The Food and Drug Administration’s emergency authorization for blood plasma as a treatment for the coronavirus has been put on hold to allow for more data to be reviewed, according to a report. An emergency approval could still be issued by the FDA in the near future, H. Clifford Lane, clinical director at the National Institute of Allergy and Infectious Diseases, told the New York Times. Several top health experts — including Dr. Anthony Fauci and Dr. Francis Collins, director of the National Institutes of Health — intervened last week, saying that data on the treatment was too weak, two senior administration officials told the newspaper. Donated by patients who have survived COVID-19, antibody-rich plasma has been deemed safe, but clinical trials have not proved whether it can help people fighting the disease. Fauci, a member of the White House coronavirus task force, Lane and Collins urged fellow experts to hold off, citing emerging data from the country’s largest plasma study by the Mayo Clinic. “The three of us are pretty aligned on the importance of robust data through randomized control trials, and that a pandemic does not change that,” Lane told the Times on Tuesday. The emergency authorization was based on the history of plasma’s use in other disease outbreaks, as well as on animal research and several studies, including Mayo’s program, the paper reported. SEE ALSO Researchers from the FDA studied 20,000 patients who doctors believed might progress to severe or life-threatening stages of COVID-19, according to a recent CNN report. They received the so-called convalescent plasma between April 3 and June 11 for the study, which was published in Mayo Clinic Proceedings. The treatment — which has been used to treat measles, influenza and Ebola — takes advantage of the fact that people who recover from an infection develop virus-fighting antibodies in their blood. Transfusions of their convalescent plasma — the clear liquid after blood cells are removed — may give the immune systems of recipients a boost in fighting off the virus. FILED UNDER ANTHONY FAUCI , BLOOD ,